BRCA2 and cancer: To explore whether small-molecule inhibitors can sensitize cancer cells to PARPi, we performed a drug combination screen in BRCA1-deficient breast cancer cell line of HCC1937 and BRCA2-deficient CRC cell line of HCT-15, which express mutant-type BRCA1 or BRCA2 protein but modestly respond to PARPi.